16.59
-0.49 (-2.87%)
| Penutupan Terdahulu | 17.08 |
| Buka | 17.00 |
| Jumlah Dagangan | 4,405,812 |
| Purata Dagangan (3B) | 2,780,711 |
| Modal Pasaran | 2,099,515,136 |
| Harga / Jualan (P/S) | 3.62 |
| Harga / Buku (P/B) | 3.03 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| Margin Keuntungan | -25.14% |
| Margin Operasi (TTM) | -31.33% |
| EPS Cair (TTM) | -1.30 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 9.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 11.33% |
| Nisbah Semasa (MRQ) | 5.37 |
| Aliran Tunai Operasi (OCF TTM) | 56.74 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 95.16 M |
| Pulangan Atas Aset (ROA TTM) | -12.43% |
| Pulangan Atas Ekuiti (ROE TTM) | -22.03% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Health Information Services (US) | Bercampur | Bercampur |
| Health Information Services (Global) | Bercampur | Bercampur | |
| Stok | 10x Genomics, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | -1.5 |
| Osilator Teknikal | 4.0 |
| Purata | -0.40 |
|
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China). |
|
| Sektor | Healthcare |
| Industri | Health Information Services |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 1.93% |
| % Dimiliki oleh Institusi | 101.82% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 20.00 (Morgan Stanley, 20.56%) | Pegang |
| Median | 18.00 (8.50%) | |
| Rendah | 14.00 (UBS, -15.61%) | Pegang |
| Purata | 17.33 (4.46%) | |
| Jumlah | 2 Beli, 4 Pegang | |
| Harga Purata @ Panggilan | 15.92 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Morgan Stanley | 02 Dec 2025 | 20.00 (20.55%) | Pegang | 17.94 |
| Piper Sandler | 11 Nov 2025 | 19.00 (14.53%) | Pegang | 16.59 |
| 11 Sep 2025 | 15.00 (-9.58%) | Pegang | 13.06 | |
| Barclays | 07 Nov 2025 | 17.00 (2.47%) | Beli | 15.25 |
| Canaccord Genuity | 07 Nov 2025 | 19.00 (14.53%) | Beli | 15.25 |
| JP Morgan | 07 Nov 2025 | 15.00 (-9.58%) | Pegang | 15.25 |
| UBS | 07 Nov 2025 | 14.00 (-15.61%) | Pegang | 15.25 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| HINDSON BENJAMIN J. | - | 20.13 | -8,283 | -166,737 |
| SAXONOV SERGE | - | 20.13 | -13,261 | -266,944 |
| TAICH ADAM | - | 20.13 | -11,888 | -239,305 |
| Jumlah Keseluruhan Kuantiti Bersih | -33,432 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -672,986 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 20.13 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| SAXONOV SERGE | Pegawai | 24 Nov 2025 | Jual (-) | 13,261 | 20.13 | 266,944 |
| HINDSON BENJAMIN J. | Pegawai | 24 Nov 2025 | Jual (-) | 8,283 | 20.13 | 166,737 |
| TAICH ADAM | Pegawai | 24 Nov 2025 | Jual (-) | 11,888 | 20.13 | 239,305 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 18 Nov 2025 | Pengumuman | New ASTRA Consortium Unites Asia-Pacific Scientists to Build Pan-Cancer Spatial Atlas Powered by 10x Genomics' Xenium |
| 11 Nov 2025 | Pengumuman | 10x Genomics to Participate in the Wolfe Research Healthcare Conference 2025 |
| 06 Nov 2025 | Pengumuman | 10x Genomics Reports Third Quarter 2025 Financial Results |
| 29 Oct 2025 | Pengumuman | 10x Genomics Launches the Next Generation of Chromium Flex to Empower Scientists to Massively Scale Single Cell Research |
| 20 Oct 2025 | Pengumuman | 10x Genomics and Anthropic Partner to Make Single Cell and Spatial Analysis More Accessible Through Claude for Life Sciences |
| 09 Oct 2025 | Pengumuman | 10x Genomics to Report Third Quarter 2025 Financial Results on November 6, 2025 |
| 09 Sep 2025 | Pengumuman | CLISEQ, 10X Genomics and Weizmann Institute to Investigate Single Cell Applications in Hematology Clinical Diagnostics |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |